ArticleJournal of cellular and molecular medicine2017
p53 regulates ERK1/2/CREB cascade via a novel SASH1/MAP2K2 crosstalk to induce hyperpigmentation.
Article in Journal of cellular and molecular medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 32 citations in OpenAlex.
- Genetic Pigmentary Disorders: From Molecular Mechanisms to Clinical Manifestations.The Journal of dermatology · 2026Review
- Dyschromatosis universalis hereditaria withSkin health and disease · 2025Review
- RAF1 in AgRP neurons involved in the regulation of energy metabolismJournal of biomedical research · 2025Article
- The downregulation of SASH1 expression promotes breast cancer occurrence and invasion accompanied by the activation of PI3K-Akt-mTOR signaling pathway.Scientific reports · 2024Article
- The PER3Journal of molecular medicine (Berlin, Germany) · 2023Article
- Novel missense mutation of SASH1 in a Chinese family with dyschromatosis universalis hereditaria.BMC medical genomics · 2021Article
- Two novel SASH1 mutations in Chinese families with dyschromatosis universalis hereditaria.Journal of clinical laboratory analysis · 2021Article
- SASH1 is a prognostic indicator and potential therapeutic target in non-small cell lung cancer.Scientific reports · 2020Article
- Mutated SASH1 promotes Mitf expression in a heterozygous mutated SASH1 knock‑in mouse model.International journal of molecular medicine · 2020Article
- Synaptotagmin-4 promotes dendrite extension and melanogenesis in alpaca melanocytes by regulating CaCell biochemistry and function · 2020Article
- The evolutionarily conserved MAPK/Erk signaling promotes ancestral T-cell immunity in fish via c-Myc-mediated glycolysis.The Journal of biological chemistry · 2020Article
- Identification of a Novel Mutation inFrontiers in genetics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported that three point mutations in SASH1 and mutated SASH1 promote melanocyte migration in dyschromatosis universalis hereditaria (DUH) and a novel p53/POMC/Gαs/SASH1 autoregulatory positive feedback loop is regulated by SASH1 mutations to induce pathological hyperpigmentation phenotype. However, the underlying mechanism of molecular regulation to cause this hyperpigmentation disorder still remains unclear. In this study, we aimed to investigate the molecular mechanism undergirding hyperpigmentation in the dyschromatosis disorder. Our results revealed that SASH1 binds with MAP2K2 and is induced by p53-POMC-MC1R signal cascade to enhance the phosphorylation level of ERK1/2 and CREB. Moreover, increase in phosphorylated ERK1/2 and CREB levels and melanogenesis-specific molecules is induced by mutated SASH1 alleles. Together, our results suggest that a novel SASH1/MAP2K2 crosstalk connects ERK1/2/CREB cascade with p53-POMC-MC1R cascade to cause hyperpigmentation phenotype of DUH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.